Immunity, Age, and Luminal Breast Cancer: Understanding the Holy Trinity
Author(s)
Salgado, R; Kok, M;
Details
Publication Year 2026-06-01,Volume 32,Issue #11,Page 2133-2135
Journal Title
Clinical Cancer Research
Publication Type
Commentary
Abstract
In 390 patients with stage I to III hormone receptor-positive/HER2- breast tumors, a higher number of tumor-infiltrating lymphocytes (TIL) subtypes, regardless of whether they were immunostimulatory or immunosuppressive, including regulatory T cells and CD8 and non-CD8 T cells, are associated with improved distant disease-free survival and overall survival at 8 years follow-up. See related article by Tesch et al., p. 2268.
Publisher
American Association for Cancer Research
Keywords
Humans; *Breast Neoplasms/immunology/pathology/mortality; Female; *Lymphocytes, Tumor-Infiltrating/immunology/metabolism; Age Factors; Erb-b2 Receptor Tyrosine Kinases/metabolism; Neoplasm Staging; T-Lymphocytes, Regulatory/immunology
Department(s)
Laboratory Research
Open Access at Publisher's Site
https://doi.org/10.1158/1078-0432.Ccr-25-4035
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2026-06-23 03:42:08
Last Modified: 2026-06-23 03:42:14
An error has occurred. This application may no longer respond until reloaded. Reload 🗙